Heart Failure

Management of Complex Cardiovascular Problems: The Evidence-based Medicine Approach

Volumn , Issue , 2007, Pages 219-253

  Nguyen, Thach N ^a,b,c,d,e,f   Pham, Loan T ^g   Vinh, Pham Nguyen ^h,i   Uy, Norbert Lingling D ^j,k,l   Kumar, Gaurav ^m   Pham, Hoang ⁿ  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d PLA Hospital No 301   (China)

^e INDIANA UNIVERSITY   (United States)

^f St Mary Medical Center   (United States)

^g KAISER PERMANENTE   (United States)

^h Department of Pediatric Nephrology   (Viet Nam)

ⁱ Pasteur Institute of Ho Chi Minh City   (Viet Nam)

^j University of the East   (Philippines)

^k UERM   (Philippines)

^l PHILIPPINE HEART CENTER   (Philippines)

^m UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

ⁿ SAINT VINCENT HOSPITAL   (United States)

more..

Author keywords

Abnormality; Cardiomyopathy; Heart failure; Hospitalization; Mortality

Indexed keywords

EID: 84889405931     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470750858.ch8     Document Type: Chapter

References (42)

1. Hunt SA, Abraham WT, Chin MH et al. The ACC/AHA Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. JACC 2005;46: 1116-1143.
2. Gersh B. Revascularization Decisions in Heart Failure: Who Needs Viability Assessment? www.cardiosource.com/ExpertOpinions/accel/interviewdetail.asp?interviewID=116 (Cardiosource accessed 5/14/06).
3. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;3:327.
4. Packer M, Bristow MR, Cohn JN et al., for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.
5. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658.
6. Ramipril. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
7. Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-convertingenzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333(25):1670-1676.
8. Tepper D. Frontiers in congestive heart failure: Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. Congest Heart Fail 1999;5:184-185.
9. Hjalmarson A, Goldstein S, Fagerberg B et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283(10):1295-1302.
10. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-the losartan heart failure survival study ELITE II. Lancet 2000;355:1582-1587.
11. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. The Valsartan Heart Failure Trial Investigators. N Engl J Med 2001;345:1667-1675.
12. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez Aet al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
13. Taylor AL, Ziesche S, Yancy C et al. for the African-American Heart Failure Trial Investigators. Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. N Engl J Med 2004;351:2049-2057.
14. Shimoni S, Frangogiannis NG, Aggeli CJ et al. Identification of hibernating myocardium with quantitative intravenous myocardial contrast echocardiography: comparison with dobutamine echocardiography and thallium-201 scintigraphy. Circulation 2003;107:538-544.
15. La Canna G, Rahimtoola SH, Visioli O et al. Sensitivity, specificity, and predictive accuracies of non-invasive tests, singly and in combination, for diagnosis of hibernating myocardium. Eur Heart J 2000;21:1358-1367.
16. Wajg JM, Cwajg E, Nagueh SF et al. End-diastolic wall thickness as a predictor of recovery of function in myocardial hibernation:relation to reST-redistribution T1-201 tomography and dobutamine stress echocardiography. J Am Coll Cardiol 2000;35:1152-1161.
17. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis. J Am Coll Cardiol 2002;39:1151-1158.
18. Tarakji KJ, Brunken R, McCarthy PM et al. Myocardial Viability Testing and the Effect of Early Intervention in Patients With Advanced Left Ventricular Systolic Dysfunction. Circulation 2006;113:230-237.
19. Hohnloser SH, Kuck KH, Dorian P et al., for the DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481-2488.
20. CABG-Patch Trial Investigators. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass surgery. N Enl J Med 1997;337:1569-1575.
21. Moss AJ, Zareba W, Hall WJ et al., for the Multicenter Automatic Defibrillator Implantation Trial II Investigators Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction. Circulation 346:877-883.
22. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-237.
23. Colucci WAS, Kolias TJ, Adams KR et al. Metoprolol reverses LV remodeling in patients with asymptomatic systolic dysfunction: The REVERT trial. Recent and late breaking clinical trials. Program and abstracts from the 9th Annual Scientific Meeting of the Heart Failure Society of America, September 18-21, 2005, Boca Raton, Florida.
24. Adams KF, Lindenfeld J, Arnaold JMO et al. Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Cardiac Failure 2006;12:10-38.
25. Fonarow GC, Adams KF Jr, Abraham WT et al. for the ADHERE Scientific Advisory Committee, Study Group, and Investigators Risk Stratification for In-Hospital Mortality in Acutely Decompensated Heart Failure Classification and Regression Tree Analysis. JAMA 2005;293:572-580.
26. Publication Committee for the VMAC Investigators Intravenous Nesiritide vs. Nitroglycerin for Treatment of Decompensated Congestive Heart Failure A Randomized Controlled Trial. JAMA 2002;287:1531-1540.
27. Sackner-Bernstein JD, Kowalski M, Fox M et al. short-term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure A Pooled Analysis of Randomized Controlled Trials. JAMA 2005;293:1900-1905.
28. Norman K. Hollenberg. Angiotensin Receptor Blockers: What Is Their Current Status? Medscape Cardiology www.medscape.com/viewarticle/511795 (accessed 5/14/06).
29. Granger CB, McMurray JJ, Yusuf S, and the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARMAlternative trial. Lancet 2003;362:772-776.
30. Nelson GS, Berger RD, Fetics BJ et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation 2000;102:3053-3059. [Erratum, Circulation 2001;103:476.].
31. Bristow MR, Saxon LA, Boehmer J for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure for the COMPANION Investigators. Cardiacresynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure N Engl J Med 2004;350:2140-2150.
32. Cleland JG, Daubert JC, Erdmann E et al., for the Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure. Circulation 352:1539-1549.
33. Weinfeld MS, Chertow GM, Warner Stevenson L. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 1999;138(2 Pt 1):285-290.
34. Costanzo MR, Saltzberg M, O'Sullivan J, Sobotka P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol 2005;46:2047-2051.
35. Foody JM, Shah R, Galusha D et al. Statins and Mortality Among Elderly Patients Hospitalized With Heart Failure. Circulation 2006;113:1086-1092.
36. Rigatelli G, Zanon F. Stem cell Therapy for Failing Hearts: There is Something Else Beyond the Cells The Journal of Geriatric Cardiology, 9/2006 (in press).
37. Law PK, Law DM, Lu P et al. Review: Human Myoblast Genome Therapy The Journal of Geriatric Cardiology, 9/2006 (in press).
38. Chat Dang. Muscling Up Damaged Hearts through Cell Therapy The Journal of Geriatric Cardiology, 9/2006 (in press).
39. Long J, Kfoury, Slaughter M et al. Long term "Destination Therapy" with the Hearmat® XVE Left ventricular Assist Device: Improved outcomes since the Rematch Study (in press).
40. Slaughter M, Deng M. Permanent Mechanical Circulatory support in Frazier OH, Kirklin JK editors Mechanical Circulatory Support. Elsevier 2006.
41. Rose E, Gelinjns AC, Moskowitz AJ et al. Long term use of a LVAD for end stage HF. NEJM 2001;345:1453-43.
42. Slaughter M. Destination therapy: A future is arriving. Congestive Heart Fail (in press).